Cancer stem cells (CSCs) are cancer cells that possess characteristics associated with normal stem cells. CSCs are therefore tumorigenic and may generate tumors through the stem cell processes of self-renewal and differentiation into multiple cell types. Such cells are hypothesized to persist in tumors as a distinct population and cause relapse and metastasis by giving rise to new tumors. Therefore, development of specific therapies targeted at CSCs holds hope for improvement of survival and quality of life of cancer patients, especially for patients with metastatic disease.
International Symposium of Advances in Cancer Stem Cell Therapeuticswill encompass cutting-edge research and findings in cancer stem cells technologies, cancer stem cells therapies and transplantation, current understanding of cell plasticity and microenvironment in cancer and other advancements in cancer stem cells research.
International Symposium of Advances in Cancer Stem Cell Therapeuticswill feature world-renowned keynote speakers in the field and will be a great platform for academicians, scientists, clinicians, business associates and graduate students to share their current findings in cancer stem cell research.
Date: 24th-25th August, 2019
Venue: Zhengzhou University, Henan, China
Venue
The conference center at YingBin Hotel of The Yellow River, Henan
Yingbin Road No.1, Zhengzhou City, Henan Province, China. http://123.58.4.25:8088/default
Confirmed Speakers
1. Tariq Enver Professor, Stem Cell Lab, Department of Cell Biology, University College London Cancer Institute. Research interest: mechanisms by which tissue and developmental stage specific gene expression is achieved and regulated; insight into how blood stem cells are configured in molecular terms, the nature of the pathways involved in their cell fate decisions, and how these are corrupted by chimaeric transcription factors associated with human leukaemia.
2. Luis F. Parada PhD Director, Brain Tumor Center; Albert C. Foster Chair; American Cancer Society Research Professor, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Research focus: neurofibromatosis, brain tumors, cancer stem cells, and tumor progression.
3. John DiGiovanni PhD Professor, Director of Center for Molecular Carcinogensis and Toxicology, University of Texas Austin, TX, USA. Research interest: i) identifying critical targets and mechanisms involved in the initiation and promotion stages of chemical as well as UV skin carcinogenesis; ii) identification of genetic determinants of susceptibility to chemically-induced skin cancer; iii) exploring novel prevention strategies for inhibiting chemical and UV skin carcinogenesis; and iv) development of new mouse models for cancer, including models for skin, prostate and head and neck cancers.
4.Dr Dingxiao Zhang PhD Professor, College of Biology, Hunan University, China. Research Interest: Functional cancer genomics, Prostate cancer stem cells, Targeted therapy and Mechanisms of prostate cancer progression
5. Dean G. Tang MD PhD Chair and Professor of Oncology, Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Research interests: stem cell development; cancer stem cells; cancer cell heterogeneity; prostate cancer and non-coding RNAs
6. Yong Li MD PhD Associate Professor of Faculty of Medicine, Principal Scientific Officer and Director of Cancer Research Laboratory St. George Hospital, UNSW Sydney, NSW, Australia. Research interests: prostate cancer; breast cancer; cancer stem cells; mechanisms of radio-/chemo-resistance.
7. Suling Liu PhD Professor, Institute of Biomedical Sciences, Fudan University; Fudan University Cancer Institute; Shanghai, China. Research interests: tumour microenvironment, signaling pathways and small RNA in breast cancer stem cells.
8. Quan Chen PhD Professor, State Key Laboratory of Membrane Biology , Institute of Zoology, Chinese Academy of Sciences, Beijing, China. Research interests: mitochondrial dynamics and mitophagy; cancer stem cells in carcinogenesis and metastasis.
9. Hao Zhang MD PhD Professor, Director, Institute of Tumour Precision Medicine and Pathology, School of Medicine, Jinan University, Guangdong, China. Research interest: inflammation and cancer; cancer stem cells; exosomal liquid biopsy and cancer immunotherapy.
10. Yong Sang Song MD PhD Professor, Department of Obstetrics and Gynecology; Chairman, Graduate School of Cancer Biology, Seoul National University; Director, Division of Gynecologic Oncology Cancer Center, Seoul National University Hospital, Seoul, Korea. Research interest: Precision medicine in ovarian cancer, tumour-microenvironment, cancer cell metabolism and chemoresistance.
11. Seong-Jin Kim Professor, Director, Precision Medicine Research Center, Advanced Institutes of Convergence Technology, Seoul National University, Seoul, Korea. Research focus: TGF-beta and their receptors in normal physiology and pathology, including inflammation, chemoprevention and carcinogenesis.
12. Anna Dubrovska PhD Professor, National Center for Radiation Research in Oncology,Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany. Her research interests is characterization of new CSC based biomarkers for the development of predictive tests based on CSC density, distribution and sensitivity to therapy.
13. Qi-en Wang MD PhD Associate Professor, Division of Radiobiology, Department of Radiology, College of Medicine, the Ohio State University, OH, USA. Research focus: cancer stem cell, DNA damage repair and chemotherapy resistance and ovarian cancer.
14.Jichao Qin,Professor and Deputy Director of GI Surgery, TongjiHospital, Huazhong University of Science and Technology, China
15.Noriko Gotoh, Professor, Cancer Cell Biology, Cancer Research Institute, Kanazawa University, Japan. Research interest: receptor tyrosine kinase, cancer stem cells, metabolism, breast cancer, lung cancer.
16.Richard Eckert, John F.B. Weaver Professor and Chair, Biochemistry and Molecular Biology, School of Medicine, University of Maryland. Associate Director for Basic Science in the University of Maryland Greenebaum Comprehensive Cancer Center. Research interest: surface epithelial biology, specifically human epidermis, skin cancer and psoriasis.
17. Young-Joon Surh, Director and Professor, College of Pharmacy, Seoul National University, Korea. Research Interest: Biochemical and molecular mechanisms underlying cancer chemopreventive activities of selected edible and medicinal phytochemicals; Intracellular signal transduction pathways mediating inflammation-associated carcinogenesis.
18. Toru Kondo, Professor, Institute for Genetic Medicine, Hokkaido University, Japan. Research Interest: Neural development, brain tumors, aging, and age-related diseases.
19. Xin Chen MD PhD Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China. Research Interest: Prostate cancer stem cell plasticity, biomarker discovery and mechanisms of hormone-resistance.
20. Danny N Dhanasekaran PhD Samuel Noble Foundation Endowed Chair in Cancer Biology & Professor of Cell Biology, Director, SCC-COBRE & Center for Basic Cancer Research, Deputy Director for Basic Research. Stephenson Cancer Center, University of Oklahoma Health Sciences Center.Research Interest: Ovarian and Pancreatic Cancer research, Signaling networks, Non-coding RNAs.
Committee
Symposium Organizers
Nicholas Lemoine, Zhengzhou University, Henan, China
Yong Li, Zhengzhou University, Henan, China
Dean G. Tang, Roswell Park Comprehensive Cancer Center, NY, USA.
